The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2020 | ETOP/IFCT 4-12 STIMULI updates from ESMO 2020
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, discusses the results from the ETOP/IFCT 4-12 STIMULI trial (NCT02046733). The trial investigated the consolidation of ipilimumab and nivolumab in limited-stage small-cell lung cancer compared with standard chemo-radiotherapy treatment alone and found no progression-free survival or overall survival advantage. Prof. Popat proposes that this may be due to high discontinuation rates resulting from the incidence of Grade 3+ immune-related adverse events. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
